JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma by unknown
RESEARCH Open Access
JunB promotes cell invasion, migration and
distant metastasis of head and neck
squamous cell carcinoma
Hiroshi Hyakusoku1, Daisuke Sano1,2* , Hideaki Takahashi1,2, Takashi Hatano1, Yasuhiro Isono1, Shoko Shimada1,
Yusuke Ito3, Jeffrey N. Myers4 and Nobuhiko Oridate1,2
Abstract
Background: While treatment failure in cases of head and neck squamous cell carcinoma (HNSCC) frequently
takes the form of locoregional recurrences and distant metastasis, our understanding of the mechanisms of
metastasis in HNSCC is limited. We initially performed the upstream and key nodes analysis together with whole
gene microarray analysis characterized by distant metastatic potential in vivo with HNSCC cell lines and identified
JunB, a member of the activator protein-1 (AP-1) family, as a key molecule in the regulation of the pathways
related to distant metastasis in HNSCC. We have therefore tested the hypothesis that JunB plays a crucial role in
distant metastasis in HNSCC.
Methods: To study the role of JunB on metastatic potential of HNSCC, small interfering RNA (siRNA)-mediated
knockdown and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9
(cas9) system (CRISPR/Cas9)-mediated knockout of JunB in HNSCC cells were established and the abilities of cell
invasion and migration in vitro were examined. The efficacy of knockout of JunB was also examined using an
experimental lung metastatic mouse model of HNSCC. In addition, to study if the role of JunB in HNSCC cell
migration and invasiveness is related to epithelial-to-mesenchymal transition (EMT), cell morphology and
expression of mesenchymal or epithelial marker on siRNA mediated JunB knockdown in HNSCC cells were
examined with or without TGF-β stimulation.
Results: siRNA knockdown and sgRNA knockout of JunB in metastatic HNSCC cells significantly suppressed both
cell invasion and migration in vitro. In addition, the knockout of JunB in metastatic HNSCC cells significantly
repressed the incidence of lung metastases and prolonged the survival in vivo. However, we did not observe any
change in cell morphology with the down-regulation of mesenchymal markers and up-regulation of epithelial
markers in response to siRNA-mediated JunB knockdown in HNSCC cells.
Conclusion: These results suggested that JunB could play an important role in promoting cell invasion, migration
and distant metastasis in HNSCC via pathways other than EMT and that the down-regulation of JunB may
become an effective strategy for patients with invasive HNSCC.
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Background
Head and neck squamous cell carcinoma (HNSCC) is
the sixth most frequently diagnosed cancers in the world
[1]. The survival of patients with HNSCC has not dra-
matically improved over the past several decades despite
advances in multidisciplinary treatment [2, 3]. This is be-
cause of many newly diagnosed HNSCC patients present
with advanced stage disease at diagnosis, and partly due
to our inability to control and our poor understanding
of the regional and distant spread of this disease. In fact,
most treatment failure in cases of HNSCC is due to
locoregional recurrence or distant metastatic disease
[4, 5]. Thus, it is still urgent to advance our understanding
of the mechanisms of the progression and metastasis of
HNSCC in order to improve the survival outcome for pa-
tients with HNSCC.
The transcription factor AP-1 (activator protein 1),
one of the major effectors activating gene transcription,
is a heterodimeric protein composed of Fos family (Fos,
FosB, FosL1 and FosL2), Jun family (Jun, JunB, and JunD),
Atf (activating transcription factor) and Maf (musculoapo-
neurotic fibrosarcoma) proteins [6, 7]. Phosphorylation of
Fos and Jun or extracellular stimuli such as cytokines,
stress, infection, and growth factors inducing the expres-
sion of Fos and Jun, the main AP-1 proteins in mamma-
lian cells, can activate the AP-1 pathway. The activated
AP-1 complex then binds to a consensus DNA sequence
in the promoter region to regulate AP-1 target genes ex-
pression thus playing an important role in a number of
cellular processes, including proliferation, differentiation,
apoptosis, cell migration, and transformation [8]. While
some AP-1 proteins have been reported to have tumor
suppressor activity, AP-1 is well known to have oncogenic
activity [6, 9, 10]. In fact, AP-1 activation in epithelial cells
has been reported to be required for SCC transformation
in a transgenic mouse model [11], and to promote metas-
tasis in SCC [12]. Among the AP-1 family, Jun and FosL1
have also been reported to promote invasion via
epithelial-to-mesenchymal transition (EMT) [9]. Thus, the
activation of AP-1 has been reported to play a critical role
in the invasive growth and metastasis of human cancers,
although the significance of AP-1 in metastasis in HNSCC
is not yet fully understood.
In this study, we initially characterized the distant
metastatic potential in vivo using 26 different HNSCC
cell lines in an experimental lung metastatic mouse
model with tail vein injection of HNSCC. A whole gene
microarray was performed with 8 selected HNSCC cell
lines, and upstream and key node analysis was then used
to investigate the upstream key molecules involved in
the mechanisms of distant metastasis in HNSCC. The
AP-1 family was identified as the key molecules regulating
the pathways related to distant metastasis in HNSCC. We
therefore hypothesize that the AP-1 family plays a crucial
role in inducing cell invasion, migration and distant me-
tastasis in HNSCC. In the present study, we show that the
small interfering RNA (siRNA)-mediated knockdown and
clustered regularly interspaced short palindromic repeats
(CRISPR)/CRISPR-associated protein 9 (cas9) system
(CRISPR/Cas9 [13, 14])-mediated knockout of JunB in
HNSCC cells significantly inhibited both invasion and mi-
gration in vitro, as well as lung metastasis in vivo.
Methods
Cell lines
Information on and appropriate growth media for the 26
HNSCC cell lines are shown in Additional file 1: Table S1.
All cells were authenticated by short tandem repeat geno-
typing as described previously [15, 16]. Adherent mono-
layer cultures were maintained on plastic and incubated at
37 °C and 5 % CO2.
Animals and maintenance
Athymic nude mice, aged 7–8 weeks, were purchased
from the animal production area of the National Cancer
Institute-Frederick Cancer Research and Development
Center (Frederick, MD) and Oriental Yeast (Tokyo, Japan).
The mice were housed and maintained in laminar flow
cabinets under specific pathogen-free conditions and used
in accordance with the NIH and AERI-BBRI Animal
Care and Use Guidelines under protocols approved by
the Institutional Animal Care Use Committee of the
University of Texas M.D. Anderson Cancer Center
(Houston, TX) and Yokohama City University School
of Medicine (Yokohama, Japan).
Experimental lung metastatic mouse model of HNSCC
The lung metastatic potential of the 26 HNSCC cells was
examined by a tail vein metastatic assay as described previ-
ously [17]. Briefly, 1.0 × 106 HNSCC cells in a volume of
200 μL were injected into the lateral tail vein using a 27-
gauge needle. Eight to 11 mice were injected with each cell
line. Mice were euthanized using carbon dioxide asphyxi-
ation when they lost more than 15 % of their pre-injection
body weight or at 90 days after cell injection. Necropsy was
performed and lungs were harvested and then weighed.
Each lung was fixed in formalin and embedded in paraffin
for hematoxylin and eosin (H&E) staining. The presence of
lung metastases was evaluated by light microscopy.
Microarray analysis and upstream and key node analysis
with ExPlain™
For the microarray analysis, total RNA was extracted
from 8 HNSCC cell lines (metastatic; HN30, YCU-T892
and KCC-T871, non-metastatic; Detroit562, PE/CA-
PJ34, KCC-M871, YCU-MS861, and YCU-M862) as de-
scribed previously [18]. Whole genome gene profiling
was performed using a SurePrint G3 Human GE 8 × 60 K
Hyakusoku et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:6 Page 2 of 12
Microarray (Agilent Technologies, Santa Clara, CA, USA).
The raw data were deposited into the Gene Expression
Omnibus (GEO, accession number: GSE67275).
Principal component analysis (PCA) was then performed
based on all the probe sets utilized in our microarray ana-
lysis. The 8 principal components were checked for differ-
ences between metastatic lines and non-metastatic lines,
and statistical significance was assessed by unpaired t-test.
Genes with an absolute fold change value > 5.5 and P <
0.05 were selected for further analysis. Upstream and key
nodes analysis with ExPlain™ (www.biobase.de) was then
performed to investigate upstream key molecules involved
in the mechanisms for distant metastasis in HNSCC as de-
scribed previously [19, 20]. Each key node is assigned a
score based on its connectivity to the pathways. Molecules
with a higher score can be considered to be key factors in
the regulation of the pathways.
Western blotting analysis
Western blot analyses were performed to determine the
expression of FosL1, c-Jun and JunB in HNSCC cell lines
as described previously [21]. Antibodies were purchased
from the following sources and used at the indicated
dilutions: FosL1 (1:1000; Cell Signaling Technologies,
Danvers, MA), c-Jun (1:1000; Cell Signaling Technologies),
JunB (1:1000; Cell Signaling Technologies), E-cadherin
(1:1000; Cell Signaling Technologies), N-cadherin (1:1000;
Santa Cruz Biotechnology, Dallas, TX) Vimentin (1:1000;
Santa Cruz Biotechnology), and α-Tubulin (1:1000; Cell
Signaling Technologies). To study TGF-β1-mediated
EMT, HNSCC cells were serum-starved overnight and
then treated with or without 2 ng/mL transforming
growth factor-β1 (TGF-β1; R&D Systems, Minneapolis,
MN) for 24 h.
siRNA-mediated knockdown of JunB in HNSCC cells
HNSCC cell lines were transiently transfected with scram-
bled control or two independent siRNAs for JUNB (siRNA
IDs: 7661 and s7662) (Life Technologies, Gaithersburg,
MD) using Lipofectamine RNAiMAX (Life Technologies)
according to the manufacturer’s instructions. JunB protein
expression levels in the JunB knockdown cells were com-
pared with that of cells transfected with a negative siRNA
control by Western blotting.
CRISPR/cas9-mediated knockout of JunB in HNSCC cells
The cloning of top and bottom oligonucleotides, anneal-
ing and ligation were performed using a GeneArt CRISPR
Nuclease Vector with a CD4 Enrichment Kit (Life
Technologies). KCC-T871 cells were transfected with
single-guide RNA (sgRNA) for two independent specific
sequences in JUNB (JunB#1 and JunB#2) or nonspecific
sgRNA using Lipofectamine 3000 (Life technologies) and
Amaxa Nucleofector 2b (Lonza, Basel, Switzerland).
Electroporation/nucleofection was performed using a Cell
Line Nucleofector kit V (Lonza) and the Nucleofector
program T-030. Control and JUNB oligonucleotides are
shown in Table 1. Single colonies were isolated using a
Dynabeads CD4 Positive Isolation Kit (Life technologies)
for further passaging.
The confirmation of the genome editing was per-
formed using a GeneArt Genomic Cleavage Detection
kit (Life technologies) with the primers shown in Table 1.
PCR products were visualized by means of an E-Gel Safe
Imager on E-GeL EX 2 % agarose (Life technologies).
JunB protein expression levels in sgRNA-transfected or
control cells were confirmed by Western blotting.
Invasion assay
In vitro tumor cell invasion was examined using Corning
Matrigel Invasion Chambers (Corning life science, Corn-
ing, NY). Briefly, 5 × 104 of KCC-T871 cells or 1 × 105 of
HN30 cells infected with scramble or JUNB siRNA in
serum-free medium were plated in the upper chamber
and incubated with medium containing 10 % fetal bovine
serum (FBS) in the bottom of the chamber for 22 h. In-
vaded cells were then stained with giemsa solution
(WAKO, Japan) and counted in all fields. The experi-
ment was repeated three times.
Scratch assay
One million KCC-T871 or HN30 cells infected with
scrambled or JUNB siRNA, or with sgControl or JUNB
sgRNA were seeded in 24-well plates and incubated with
medium containing 10 % FBS. Once confluent, a horizon-
tal wound was made in the cell layer of each well using a
200-μL pipette tip and images were captured at 0 h and
9 h post-wound for KCC-T871 and 15 h for HN30 cells.
The percentage of the wound area remaining open was
measured to assess the amount of movement during
wound closure. The experiment was repeated three times.
Table 1 Sequences of CRISPR sgRNA and confirming primers
used in this study
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Cell viability assay
Cells were seeded on 96-well microplates at the concen-
tration of 1.0 × 103 cells per well and cultured at 37 °C in
5 % CO2, and then incubated for 24, 48, 72 or 96 h. Cell
viability was evaluated by Cell Counting Kit-8 (CCK-8)
assay (Dojindo Laboratories, Kumamoto, Japan), in which
the absorbance at OD 450 nm was measured using a mi-
croplate reader (BioRad, Model 680, USA).
Experimental lung metastatic mouse model with KCC-
T871/crControl and KCC-T871/JUNB/KO#1 cells
The lung metastatic potential of KCC-T871 cells trans-
fected with the sgRNA control or sgRNA JUNB#1 was
examined using a tail vein metastatic assay. A total of
7 × 105 cells were injected into the lateral vein as de-
scribed previously [17]. Fourteen or 16 mice were pre-
pared for each cell line. Mice were euthanized using
carbon dioxide asphyxiation when they lost more than
15 % of their pre-injection body weight or at 120 days
after cell injection. The presence of lung metastasis was
confirmed by H&E staining.
The animal experiment was repeated with 6 mice for
the control and 8 mice for the sgRNA-mediated JunB
knockout group. In the repeated experiment, mice were
euthanized at 78 days after cell injection, and lungs were
then weighed to evaluate for the presence of metastasis by
light microscopy. To quantify the development of lung
metastasis in the animal model, we calculated the average
ratio of the area displaying metastatic cells in the lung to
the total area of the lung in an entire field. Three lung
slides were prepared for each mouse in this analysis.
Statistical analysis
Potential correlations between the incidence of lung me-
tastasis (%) and median survival time in the experimen-
tal lung metastasis model were analyzed using Pearson’s
correlation. Survival was analyzed by the Kaplan-Meier
method and compared using log-rank tests. The results
of the migration and invasion assay were compared
using a paired 2-tailed t test. Fisher’s exact test was used
to compare the incidences of lung metastasis. Quantita-
tive data related to median lung weight and the area dis-
playing metastatic cells in the lung were compared using
an unpaired 2-tailed t test. Statistical analyses were per-
formed with GraphPad Prism version 6.05 (GraphPad
Software, La Jolla, CA). For all comparisons, P < 0.05
was considered statistically significant.
Results
The distant metastatic potential of 26 HNSCC lines in an
experimental lung metastatic mouse model
Twenty-six HNSCC cell lines showed a wide spectrum
of distant metastatic potential in vivo. We found that 21
(80.8 %) of the 26 HNSCC cell lines produced lung
metastases (Fig. 1d, Additional file 2: Table S2). Three
HNSCC lines (HN30, KCC-T871, YCU-T892) estab-
lished 100 % lung metastases in an experimental lung
metastatic mouse model of HNSCC (Fig. 1a, c), while
five HNSCC cell lines (Detroit562, PE/CA-PJ34, KCC-
M871, YCU-MS861, YCU-M862) did not establish lung
metastasis in any of the mice injected (Fig. 1b). Survival
curves for mice injected with each of the 26 HNSCC cell
lines are shown in Additional file 3: Figure S1. The median
survival time ranged from 43.5 to 90 days. We found an
inverse correlation between the incidence of lung metasta-
sis (%) and median survival time (r = –0.5195, P = 0.0015)
(Additional file 4: Figure S2).
Microarray analysis and upstream and key node analysis
A clear separation in the 3 principal component analysis
(PCA) was observed between three metastatic HNSCC
cell lines (HN30, KCC-T871, YCU-T892) and five non-
metastatic HNSCC cell lines (Detroit562, PE/CA-PJ34,
KCC-M871, YCU-MS861, YCU-M862) (Fig. 1e). Differ-
entially expressed genes showing statistically significant
up- or down-regulations in expression between the
metastatic and non-metastatic HNSCC cell lines are
shown in Table 2.
To better understand the mechanisms underlying the
gene expression findings, the microarray data were ana-
lyzed in the context of complex regulatory networks.
One hundred and sixty-four genes with an absolute fold
change value (FC) >5.5 and P < 0.05 (unpaired t-test)
were selected, and the data were then loaded into the
ExPlain™ pathway search tool and key nodes were
searched in the upstream pathways.
One hundred and ninety-seven genes were identified
for the candidate genes as key factors in the regulation
of pathways related to distant metastasis in HNSCC. A
list of 20 genes with a score ≥11 according to the Ex-
Plain™ tool is shown Table 3. The results, which show
several AP-1 family genes such as Fos, JunB and FosL1
as having high scores, led us to hypothesize that the
AP-1 family of transcription factor plays a crucial role
in inducing cell invasion, migration and distant me-
tastasis in HNSCC.
Expression of AP-1 family proteins in HNSCC cells
The expression levels of c-Jun, FosL1 and JunB in meta-
static HNSCC cells (HN30, KCC-T871, YCU-T892) and
non-metastatic HNSCC cells (Detroit562, PE/CA-PJ34,
KCC-M871, YCU-MS861, YCU-M862) were analyzed by
Western blotting as shown in Fig. 1f. The lung meta-
static HNSCC cell lines showed higher levels of c-Jun,
FosL1 and JunB expression than did the non-metastatic
HNSCC cell lines. Although the difference in JunB ex-
pression between the metastatic and non-metastatic
HNSCC cell lines was slight, we decided to clarify the
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roles of JunB in regulating the pathways related to distant
metastasis in HNSCC based on the high scores observed
for JunB in the upstream and key node analysis for the
current dataset (distant metastatic vs. non-metastatic) and
the regional metastatic vs. non-metastatic data set (data
not shown).
siRNA knockdown and sgRNA knockout of JunB in metastatic
HNSCC cells suppresses tumor invasion and migration
To determine whether JunB promoted invasion and mi-
gration in HNSCC cells, we depleted JunB in metastatic
HNSCC cell lines (KCC-T871 and HN30), and performed
















































































































































































Fig. 1 The distant metastatic potential of 26 HNSCC lines in the experimental lung metastatic mouse model. a Lung metastasis in the experimental
lung metastatic mouse model of HNSCC. (△ metastatic lesion). b No metastasis was observed in the lungs of the mouse model. c H&E staining of lung
metastasis in the experimental lung metastatic mouse model of HNSCC (* metastatic lesion). d Incidence of lung metastasis for 26 cell lines in the
experimental lung metastatic mouse model of HNSCC. Three HNSCC cell lines (HN30, KCC-T871, YCU-T892) established 100 % lung metastases, while 5
cell lines (Detroit562, PE/CA-PJ34, KCC-M871, YCU-MS861, YCU-M862) did not establish lung metastasis in any of the mice injected. e The results of
principle component analysis (PCA). PCA was performed based on the expression profiles of samples. The first 3 PCAs for 8 HNSCC cells were plotted.
: Metastatic lines (HN30, KCC-T871, YCU-T892), : Non-metastatic lines (Detroit562, PE/CA-PJ34, KCC-M871, YCU-MS861, YCU-M862). f Expression of
AP-1 family proteins in HNSCC cells by Western blotting. The lung metastatic HNSCC cell lines (HN30, YCU-T892 and KCC-T871) showed higher levels
of c-Jun, FosL1 and JunB expression than did the non-metastatic HNSCC cell lines. α-Tubulin was used as an internal control
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KCC-T871 and HN30 were transfected with siControl
or two independent siRNAs for JUNB (#1 and #2) and
the knockdown was then confirmed by Western blotting
(Fig. 2a). The invasion assay revealed a 45.9 % reduction
in invasion potential for KCC-T871/siJUNB#1 cells
(39.8 ± 7.7) compared to scrambled siRNA control
(73.5 ± 7.0, P = 0.0003) and an 81.2 % reduction in
HN30/siJUNB#1 cells (18.4 ± 5.2) invasiveness when
compared to control (98.1 ± 27.2, P = 0.011) as shown
in Fig. 2b. Thus, the siRNA-mediated knockdown of
JunB in KCC-T871 and HN30 cells inhibited the inva-
sive potential of these cell lines.
The scratch assay revealed significant reductions in cell
motility for KCC-T871/siJUNB#1 cells (62.3 % ± 5.8 % vs.
83.6 % ± 4.4 %, P = 0.005) and KCC-T871/siJUNB#2 cells
(8.25 % ± 2.9 % vs. 34.6 % ± 2.5 %, P < 0.0001) compared
to control. Significant reductions in cell motility for
HN30/siJUNB#1 cells (16.2 % ± 5.9 % vs. 92.2 % ± 2.4 %,
P < 0.0001) and HN30/siJUNB#2 cells (60.9 % ± 2.9 %
vs. 85.6 % ± 2.3 %, P < 0.0001) compared to control were
also observed. Thus, the siRNA-mediated knockdown
of JunB in KCC-T871 and HN30 cells also inhibited the
cell migration ability as shown in Fig. 2c.
To confirm that JunB knockdown decreased cell mo-
tility and invasiveness in HNSCC cells, the JunB knock-
out cells were established with two independent sgRNAs
(JUNB/KO#1 and #2) using the CRISPR/cas9 system and
the knockout was then confirmed as shown in Fig. 3a
and b. As shown in Fig. 3c, the scratch assay showed sig-
nificant reductions in cell motility for KCC-T871/JUNB/
KO#1 cells (29.3 % ± 1.0 %) and KCC-T871/JUNB/KO#2
cells (34.2 % ± 2.1 %) compared to the control (58.1 % ±
Table 2 Top 32 lists of expressed genes showing statistically
between metastatic and non-metastatic HNSCC cells
ProbeName GeneSymbol Fold change
([100 %] vs [0 %])
Absolute
Fold change
([100 %] vs [0 %])
A_24_P393571 GDA 266.48 266.48
A_33_P3238166 PXDN 224.54 224.54
A_33_P3271455 PXDN 200.54 200.54
A_33_P3846653 KRT19P2 −160.22 160.22
A_23_P66798 KRT19 −152.13 152.13
A_23_P36658 MGST1 −148.41 148.41
A_33_P3342375 MAGEA6 114.26 114.26
A_23_P501754 CSF3 106.48 106.48
A_23_P89431 CCL2 −93.74 93.74
A_23_P23155 AJAP1 91.15 91.15
A_23_P148255 MAGEA2B 88.90 88.90
A_23_P383258 GDA 86.16 86.16
A_23_P29594 RPL39L −68.22 68.22
A_23_P29655 C3orf14 65.82 65.82
A_33_P3307363 LPHN2 −60.56 60.56
A_23_P122924 INHBA 54.27 54.27
A_32_P101031 LYPD1 −45.41 45.41
A_33_P3284129 LYPD1 −45.37 45.37
A_23_P518 VTCN1 −45.19 45.19
A_33_P3687198 LOC283454 −43.10 43.10
A_23_P135257 PRSS3 38.15 38.15
A_23_P310274 PRSS2 36.77 36.77
A_23_P43197 CALB1 −36.67 36.67
A_23_P70307 SMOC2 36.55 36.55
A_21_P0009342 LOC645638 −35.05 35.05
A_33_P3222424 CSF3 34.90 34.90
A_23_P218111 SERPINA1 34.12 34.12
A_33_P3240078 32.19 32.19
A_23_P415021 METTL7A −31.60 31.60
A_19_P00805833 LOC100287628 −31.45 31.45
A_33_P3352557 DMRTA2 −31.07 31.07
A_23_P87709 PLBD1 −30.70 30.70
One hundred sixty four genes with an absolute fold change value (FC) >5.5
and P < 0.05 were detected. Top 32 genes with an absolute FC > 30 were listed
Table 3 Top 20 lists of upstream key molecules in lung






















Microarray data were loaded into the ExPlain™ pathway search tool and key
nodes were searched in the upstream pathways. Each key node is assigned a
score based on its connectivity of the pathways. Molecules with higher score
could be considered as key factors regulating the pathways related with
distant metastasis of HNSCC
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2.5 %, P < 0.0001 and P < 0.0001, respectively), which
was consistent with our previous results. These results
suggested that JunB could promote HNSCC cell migration
and invasion. On the other hand, the cell proliferation
ability of KCC-T871, KCC-T871/crControl, KCC-T871/
JUNB/KO#1 and KCC-T871/JUNB/KO#2 were similar in
cell viability assays (Fig. 3d).
As JunB has been reported to contribute transforming
growth factor-β-induced EMT [22], we next examined if
the role of JunB in HNSCC cell migration and invasiveness
is related to EMT. KCC-T871 cells showed mesenchymal
characteristics at baseline as well as E-cadherin expression.
Their cell morphology did develop any epithelial character-
istics upon siRNA-mediated JunB knockdown in KCC-
T871 cells with or without TGF-β stimulation. In addition,
no phenomena associated with the down-regulation of
mesenchymal markers and up-regulation of epithelial
markers were observed with or without TGF-β stimulation
as shown in Additional file 5: Figure S3. Furthermore,
we did not observe any change in cell morphology
with the down-regulation of mesenchymal markers

























































Fig. 2 siRNA knockdown of JunB in metastatic HNSCC cells suppresses tumor invasion and migration. a Western blotting analysis of KCC-T871
and HN30 cells transfected with scramble or JUNB siRNAs (#1 and #2). b siRNA knockdown of JunB in HN30 and KCC-T871 cells inhibited cell
invasion. Columns, mean number of cells; bars, SEM. *P < 0.05, **P < 0.01. c siRNA knockdown of JunB in HN30 and KCC-T871 cells inhibited cell
migration. Columns, mean number of cells; bars, SEM. **P < 0.01, ***P < 0.001
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sgRNA-mediated JunB knockout in KCC-T871 cells
(data not shown).
Knockout of JunB in metastatic HNSCC cells reduced the
incidence of lung metastasis in vivo
To clarify the role of JunB in cell migration and invasive-
ness in HNSCC in vivo, the effect of knocking out of
JunB was examined using an experimental lung meta-
static mouse model. Fourteen mice for the control group
with KCC-T871/crControl and 16 mice for the JunB
knockout (KO) group with KCC-T871/JUNB/KO#1 were
prepared for the survival study. The median survival
period for the JunB KO group (120.0 days) was signifi-
cantly greater than that for the control group (105.5 days,
P = 0.0002, Fig. 4a). The presence of microscopic lung
metastasis lesions was also impacted as 100 % of control
animals had lung metastases, while 75.0 % of animals in
the JunB KO group were found to have lung metastases
as shown in Additional file 6: Figure S4a (P = 0.1029).
To confirm that JunB knockout reduced the incidence
of lung metastasis in the animal model, the in vivo study
was repeated to measure the weight of each lung and
the area occupied by metastatic HNSCC cells in the lung
at 78 days after cell inoculation (6 mice were used for
the control group and 8 mice for the JunB KO group).
Microscopic lung metastasis was detected in 83.3 % of the
control mice and 62.5 % of the JunB KO mice (P = 0.209,
Additional file 6: Figure S4b). Median lung weight was
0.325 g for the control group (0.26–1.16 g) and 0.26 g for
JunB KO group (0.26–0.34 g) as shown in Fig. 4e. Thus,
JunB knockout markedly reduced lung weight in the
animal model; however, the difference was not significant
(P = 0.0727). On the other hand, we observed that JunB
knockout significantly reduced area occupied by meta-
static HNSCC cells in the lung in the experimental lung
metastatic mouse model (Additional file 7: Figure S5). As
shown in Fig. 4f, the mean percentage of metastatic
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Fig. 3 sgRNA knockout of JunB in metastatic HNSCC cells suppresses tumor migration but not cell proliferation. a Western blotting analysis of
KCC-T871 cells transfected with control sgRNA or JUNB sgRNA (#1 and #2). b The confirmation of genome-editing in KCC-T871 cells transfected
with sgRNA-mediated JunB knockout. The efficiency of sgRNAs targeting JunB was measured using a GeneArt Genomic Cleavage Detection kit.
c sgRNA knockout JunB in KCC-T871 cells inhibited cell migration. Columns, mean % of wound closure; bars, SEM. **P < 0.01 ***P < 0.001. d The
cell proliferation ability of KCC-T871, KCC-T871/crControl, KCC-T871/JUNB/KO#1 and KCC-T871/JUNB/KO#2 were all similar in the cell viability assay
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(0–95.6 %) and 1.6 % for the JunB KO group (0–9.4 %,
P = 0.0037). Overall, we observed that knockout of JunB
in metastatic HNSCC cells markedly reduced the in-
cidence of lung metastasis in an experimental lung
metastatic mouse model.
Discussion
In this study, we identified AP-1 family as key molecules
regulating the pathways related to distant metastasis in
HNSCC using the upstream and key node analysis to-
gether with whole gene microarray analysis based on the
Fig. 4 Lung metastasis was reduced in JUNB-knockout KCC-T871 cells in the experimental lung metastatic mouse model. a Survival time
of the control group with KCC-T871/crControl (N = 14) and JunB knockout (KO) group with KCC-T871/JUNB/KO#1 (N = 16). The survival rate
for the control group was significantly lower than that for the JunB KO group. ***P < 0.001. b Median lung weight of the control and
JunB KO groups. Median lung weight of mice in the control group was significantly heavier than for that for the JunB KO group. P = 0.001, Boxes, 25th,
50th and 75th percentiles; bars, 10th and 90th percentiles. c Hematoxylin and eosin (H&E) slides of the lung from a mouse injected with KCC-T871/
crControl cells in the locations marked with asterisks (*). d H&E slides of the lung in a mouse injected with KCC-T871/JUNB/KO#1 cells in the locations
marked with asterisks (*). e Median lung weight of the control group (N = 6) and JunB KO group (N = 8) in the repeated animal study. JunB knockout
reduced lung weight in the animal model; however, the difference was not significant. P = 0.0727, Boxes, 25th, 50th and 75th percentiles; bars, 10th
and 90th percentiles. f The area occupied by metastatic HNSCC cells in the lung in an experimental lung metastatic mouse model. The
mean percentage of the lung area displaying metastatic HNSCC cells in the JunB KO group (N = 24) was significantly reduced compared
to that in the control group (N = 18). **P < 0.01, Boxes, 25th, 50th and 75th percentiles; bars, 10th and 90th percentiles
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in vivo metastatic potential of HNSCC cell lines. Among
the AP-1 family, we determined that the knockdown and
knockout of JunB in HNSCC cells significantly inhibited
their invasion and migration in vitro as well as the inci-
dence of lung metastases in vivo. However, no phenom-
ena related to mesenchymal-to-epithelial transition
(MET), including the depletion of morphological mesen-
chymal characteristics and mesenchymal markers, were
observed in response to the knockdown or knockout of
JunB in metastatic HNSCC cells. These results suggested
that JunB could play an important role in promoting cell
invasion, migration and distant metastasis in HNSCC
via pathways other than EMT.
While there were several candidate genes related to
the regulation of the pathways for distant metastasis in
HNSCC identified by our key node analysis, as shown in
Table 3, the AP-1 family genes were one of handful
genes with high scores in the analysis for both the
current dataset for distant metastatic vs. non-metastatic
and our previous dataset for regional metastatic vs. non-
metastatic. We previously characterized the regional
metastatic potential in vivo using HNSCC cell lines in
an orthotopic nude mouse model of HNSCC [21], and
performed the upstream and key node analysis using
almost the same method as that in the present study,
and found that JunB and c-Fos also had high scores
(data not shown). Thus, our results revealed that the
AP-1 family, including JunB, might be important for
regulating the pathways related not only to distant but
also to regional metastasis in HNSCC.
It is well known that EMT is crucial for cancer cells
not only in regard to tumor invasion and metastasis abil-
ity but also in the acquisition of resistance to apoptosis
and stemness properties [23]. During the EMT process,
cancer cells acquire mesenchymal characteristics instead
of losing epithelial features, and increased cell migration
and invasiveness is induced by stimuli or cytokines in-
cluding TGF-β. Recently, several studies showing the
contribution of the AP-1 family to the EMT process
have been reported for several malignancies [24–26]. In
fact, genome-wide profiling of AP-1–regulated transcrip-
tion has revealed that c-Jun and FosL1 promote cell in-
vasion through the repression of E-cadherin expression
by the transcriptional upregulation of ZEB2 in triple-
negative breast cancer cells [24]. FosL1/AP-1 signaling
has also been reported to modulate ZEB1/2 and TGF-β
expression to induce EMT in triple-negative breast can-
cer cells [24]. Moreover, cooperation between Twist1
and AP-1 has been reported to regulate integrin α5
expression to induce cell invasion by EMT [25]. Thus,
AP-1 is closely associated with the EMT process in pro-
moting the invasion and metastasis of cancer cells. How-
ever, contrary to these previous reports, we did not
observe any phenomena related to MET with or without
TGF-β in response to the depletion of JunB in HNSCC
cells. Among the AP-1 family members, only a few stud-
ies have sought to determine the contribution of JunB to
EMT, suggesting that the role of JunB in regulating
EMT might be less important than that of either c-Jun
and/or FosL1. There is also the possibility that the con-
tribution of AP-1 signaling to EMT in the metastatic
process in HNSCC could be relatively low compared to
those for other malignancies, as the greater number of
gene mutations existing in HNSCC cells, due to a history
of tobacco and/or alcohol use, could play an important
role in HNSCC metastasis [27].
Other mechanisms underlying the AP-1-mediated regu-
lation of tumor invasion in cancer cells have been also re-
ported. Kanno et al. reported that JunB regulates several
genes, such as matrix metalloproteinase-2 (MMP-2),
MMP-9 and chemokine (C-C motif) ligand-2 (CCL2), to
promote tumor invasion and angiogenesis in VHL-
defective renal cell carcinomas [28]. The AP-1/NFAT4
complex has also been reported to regulate the inhibition
of E-cadherin expression by microRNA-23a during Fas-
induced EMT in gastrointestinal cancer [29]. Ding et al.
have identified KDM4A (lysine-specific demethylase 4A)
as a key epigenetic factor activating JUN and FOSL1 to
promote tumor invasion and cervical lymph node metas-
tasis in HNSCC [12]. Thus, there are a number of mecha-
nisms related to the regulation of tumor invasiveness by
AP-1 in cancer cells. Further study is required to examine
the details of the cellular and molecular mechanisms
underlying the JunB-mediated promotion of tumor inva-
sion in HNSCC.
Another limitation in the present study is that we used
an experimental lung metastatic mouse model with tail
vein injection of HNSCC to characterize the in vivo
metastatic potential of HNSCC, following the identifica-
tion of the AP-1 family as key molecules related to dis-
tant metastasis in HNSCC by upstream and key node
analysis. The mouse model was also used to confirm the
role of JunB knockout in tumor metastasis in this study.
Although an experimental lung metastatic mouse model
with tail vein injection of cancer cells has been widely
used for studying distant metastatic potential, this model
may not adequately mimic human metastatic cancer
because of discrepancies in the host microenvironment in
terms of the biological metastatic procedure and the
absence of the cross-talk between primary and metastatic
lesions [30, 31]. Basically, an orthotopic mouse model is a
more adequate model with which to mimic tumor metas-
tasis in vivo, as the orthotopic mouse model has advan-
tages in terms of its ability to mimic local tumor growth
and recapitulate the pathways of metastasis through a
more comparable host microenvironment [32]. However,
it is generally difficult to observe the development of
distant metastasis in an orthotopic xenograft model of
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HNSCC, since the tongue tumors in the model do not
allow enough time for distant metastatic lesions to de-
velop biologically from the primary tumor generated by
orthotopic implantation. Moreover, Rashid et al. have
reported that an experimental lung metastatic mouse
model with tail vein injection could produce lung
metastatic lesion with similar genomic profiles as lung
metastases after orthotopic implantation [33]. An ex-
perimental lung metastatic mouse model with tail vein
injection of HNSCC was therefore used to elucidate the
key molecules regulating the pathways related to metas-
tasis in HNSCC in this study.
Conclusions
We have identified the AP-1 family as the key molecules
regulating the pathways related to distant metastasis in
HNSCC by use of upstream and key nodes analysis con-
ducted in combination with the characterization of the
in vivo distant metastatic potential of 26 different of
HNSCC cell lines in an experimental lung metastatic
mouse model. The knockdown and knockout of JunB re-
duced tumor migration and invasion in vitro as well as
lung metastasis in vivo, suggesting that the JunB path-
way might be a useful a therapeutic target for inhibiting
distant metastasis in patients with HNSCC. However, we
did not observe any phenomena related to MET in re-
sponse to JunB knockdown in HNSCC cells. Further
studies are required to examine the details of the cellular
and molecular mechanisms of the promotion tumor in-
vasion by JunB in metastatic HNSCC in order to identify
specific JunB inhibitors and demonstrate their efficacy in
inhibiting tumor invasion and metastasis in HNSCC.
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